Lexaria Bioscience CBD Study Results Expected to Demonstrate Effectiveness Against Hypertension
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week.
Related: Should you buy Lexaria Biosciences Stock?
The study, undertaken to examine the effects of DehydraTECH-CBD upon acute pulmonary hypertension, used a blinded design with administration of a single 300mg dose of a specific DehydraTECH 2.0 CBD formulation compared to placebo in a target group of sixteen enrolled volunteers. Subject to pending analysis of samples collected from the study, blood pressure results are expected to be reported soon.
Exposure to acute reductions in oxygen tension (i.e., hypoxia) causes rapid hypoxic pulmonary vasoconstriction (“HPV”) and pulmonary arterial pressure increases as a consequence of this HPV response. If the increase in pressure becomes too high, an excess of fluid in the lungs can occur that causes difficulty with breathing. The extent to which CBD may act as a novel treatment for HPV and potentially as an alternative treatment for pulmonary hypertension is unknown. Therefore, the primary objective of the study is to evaluate the effect of DehydraTECH-CBD on pulmonary vascular function in normotensive individuals exposed to hypoxia. Results from HYPER-H21-3 are expected to add to Lexaria’s growing body of evidence for the effectiveness of DehydraTECH-CBD against hypertension, and findings will be submitted to regulators such as the FDA as Lexaria pursues its planned investigational new drug research program.
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at
Lexaria Bioscience CBD Study Results Expected to Demonstrate Effectiveness Against Hypertension
Cannin Investment Group: Your Hemp Stocks Experts
Cannin.com is your trusted resource for top hemp stocks. Our team of financial experts evaluates all emerging hemp stock investing opportunities. We aggregate hundreds of hours of market research to provide tips on the best hemp stocks for 2021.
Use Cannin as your resource for:
Is it too late to invest in hemp stocks? No! This is the perfect time to invest.
Wall Street analysts expect the global cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in hemp stocks is now.
Are you interested in the best hemp stocks for 2021 like HempFusion, Inc., Charlotte’s Web, Canopy Growth, or Hemp Inc.?
Are you looking to buy stock in hemp companies or stock in cannabis companies in 2021? Interested in penny hemp stocks? Interested in leveraging the power of algorithmic stock trades to profit from hemp stocks? Looking for the best Canadian cannabis stocks? We can help.
Predict price movements of hemp stocks several hours in advance with our proprietary algorithmic stock trading software.
- +30% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
At Cannin, we’re so confident you’ll love our algotrading hemp stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best hemp stocks – we’ll show you how at cannin.com.
